ENSG00000138376 |
BARD1 |
esophageal adenocarcinoma |
missense_variant |
4.753% (26/547) |
1 entry |
ENSG00000138376 |
BARD1 |
esophageal adenocarcinoma |
sequence_alteration |
4.753% (26/547) |
1 entry |
ENSG00000138376 |
BARD1 |
pancreatic ductal adenocarcinoma |
sequence_alteration |
2.852% (48/1683) |
1 entry |
ENSG00000138376 |
BARD1 |
breast ductal adenocarcinoma |
sequence_alteration |
2.628% (42/1598) |
2 entries |
ENSG00000138376 |
BARD1 |
ovarian serous adenocarcinoma |
sequence_alteration |
0.3601% (3/833) |
1 entry |
ENSG00000138376 |
BARD1 |
bladder transitional cell carcinoma |
sequence_alteration |
1.743% (8/459) |
1 entry |
ENSG00000138376 |
BARD1 |
colon adenocarcinoma |
stop_gained |
1.334% (17/1274) |
2 entries |
ENSG00000138376 |
BARD1 |
melanoma |
sequence_alteration |
3.448% (5/145) |
3 entries |
ENSG00000138376 |
BARD1 |
prostate adenocarcinoma |
missense_variant |
1.675% (36/2149) |
2 entries |
ENSG00000138376 |
BARD1 |
colorectal adenocarcinoma |
sequence_alteration |
2.654% (31/1168) |
4 entries |
ENSG00000138376 |
BARD1 |
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
4.918% (3/61) |
1 entry |
ENSG00000138376 |
BARD1 |
anaplastic astrocytoma |
missense_variant |
1.538% (2/130) |
1 entry |
ENSG00000138376 |
BARD1 |
non-small cell lung carcinoma |
missense_variant |
4.167% (4/96) |
3 entries |
ENSG00000138376 |
BARD1 |
pancreatic neuroendocrine tumor |
sequence_alteration |
4.661% (11/236) |
1 entry |
ENSG00000138376 |
BARD1 |
chronic lymphocytic leukemia |
missense_variant |
1.122% (10/891) |
1 entry |
ENSG00000138376 |
BARD1 |
female breast carcinoma |
missense_variant |
1.873% (5/267) |
1 entry |
ENSG00000138376 |
BARD1 |
esophageal squamous cell carcinoma |
sequence_alteration |
1.608% (11/684) |
5 entries |
ENSG00000138376 |
BARD1 |
prostate adenocarcinoma |
sequence_alteration |
1.675% (36/2149) |
3 entries |
ENSG00000138376 |
BARD1 |
colon carcinoma |
sequence_alteration |
25.0% (2/8) |
1 entry |
ENSG00000138376 |
BARD1 |
prostate carcinoma |
sequence_alteration |
1.878% (8/426) |
2 entries |
ENSG00000138376 |
BARD1 |
colon adenocarcinoma |
missense_variant |
1.334% (17/1274) |
5 entries |
ENSG00000138376 |
BARD1 |
colorectal adenocarcinoma |
missense_variant |
2.654% (31/1168) |
3 entries |
ENSG00000138376 |
BARD1 |
squamous cell lung carcinoma |
missense_variant |
0.8584% (8/932) |
1 entry |
ENSG00000138376 |
BARD1 |
lobular breast carcinoma |
missense_variant |
1.277% (3/235) |
1 entry |
ENSG00000138376 |
BARD1 |
breast ductal adenocarcinoma |
frameshift_variant |
2.628% (42/1598) |
1 entry |
ENSG00000138376 |
BARD1 |
prostate adenocarcinoma |
frameshift_variant |
1.675% (36/2149) |
2 entries |
ENSG00000138376 |
BARD1 |
basal cell carcinoma |
missense_variant |
10.29% (7/68) |
2 entries |
ENSG00000138376 |
BARD1 |
lung carcinoma |
sequence_alteration |
3.604% (4/111) |
1 entry |
ENSG00000138376 |
BARD1 |
pancreatic ductal adenocarcinoma |
stop_gained |
2.852% (48/1683) |
1 entry |
ENSG00000138376 |
BARD1 |
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.111% (2/180) |
1 entry |
ENSG00000138376 |
BARD1 |
gastric intestinal type adenocarcinoma |
missense_variant |
3.529% (3/85) |
1 entry |
ENSG00000138376 |
BARD1 |
rectal adenocarcinoma |
sequence_alteration |
0.5495% (3/546) |
2 entries |
ENSG00000138376 |
BARD1 |
neoplasm |
sequence_alteration |
6.897% (2/29) |
1 entry |
ENSG00000138376 |
BARD1 |
lobular breast carcinoma |
sequence_alteration |
1.277% (3/235) |
1 entry |
ENSG00000138376 |
BARD1 |
Mixed Lobular and Ductal Breast Carcinoma |
sequence_alteration |
4.918% (3/61) |
1 entry |
ENSG00000138376 |
BARD1 |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
2.009% (13/647) |
1 entry |
ENSG00000138376 |
BARD1 |
clear cell renal carcinoma |
sequence_alteration |
0.6008% (9/1498) |
3 entries |
ENSG00000138376 |
BARD1 |
cecum adenocarcinoma |
sequence_alteration |
3.042% (8/263) |
1 entry |
ENSG00000138376 |
BARD1 |
large cell lung carcinoma |
missense_variant |
10.53% (2/19) |
2 entries |
ENSG00000138376 |
BARD1 |
anaplastic astrocytoma |
sequence_alteration |
1.538% (2/130) |
1 entry |
ENSG00000138376 |
BARD1 |
breast carcinoma |
missense_variant |
0.5976% (9/1506) |
1 entry |
ENSG00000138376 |
BARD1 |
lung adenocarcinoma |
missense_variant |
1.431% (39/2726) |
6 entries |
ENSG00000138376 |
BARD1 |
breast ductal adenocarcinoma |
missense_variant |
2.628% (42/1598) |
2 entries |
ENSG00000138376 |
BARD1 |
gastric adenocarcinoma |
sequence_alteration |
1.25% (9/720) |
3 entries |
ENSG00000138376 |
BARD1 |
colon adenocarcinoma |
frameshift_variant |
1.334% (17/1274) |
1 entry |
ENSG00000138376 |
BARD1 |
ovarian serous adenocarcinoma |
missense_variant |
0.3601% (3/833) |
1 entry |
ENSG00000138376 |
BARD1 |
esophageal squamous cell carcinoma |
missense_variant |
1.608% (11/684) |
5 entries |
ENSG00000138376 |
BARD1 |
brain glioblastoma |
missense_variant |
0.4125% (5/1212) |
2 entries |
ENSG00000138376 |
BARD1 |
cecum adenocarcinoma |
missense_variant |
3.042% (8/263) |
1 entry |
ENSG00000138376 |
BARD1 |
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
2.009% (13/647) |
1 entry |
ENSG00000138376 |
BARD1 |
colon adenocarcinoma |
sequence_alteration |
1.334% (17/1274) |
5 entries |
ENSG00000138376 |
BARD1 |
skin melanoma |
missense_variant |
0.9466% (11/1162) |
3 entries |
ENSG00000138376 |
BARD1 |
lung adenocarcinoma |
sequence_alteration |
1.431% (39/2726) |
7 entries |
ENSG00000138376 |
BARD1 |
female breast carcinoma |
sequence_alteration |
1.873% (5/267) |
1 entry |
ENSG00000138376 |
BARD1 |
small cell lung carcinoma |
sequence_alteration |
0.6787% (3/442) |
2 entries |
ENSG00000138376 |
BARD1 |
skin melanoma |
sequence_alteration |
0.9466% (11/1162) |
5 entries |
ENSG00000138376 |
BARD1 |
squamous cell lung carcinoma |
sequence_alteration |
0.8584% (8/932) |
1 entry |
ENSG00000138376 |
BARD1 |
gastric intestinal type adenocarcinoma |
sequence_alteration |
3.529% (3/85) |
2 entries |
ENSG00000138376 |
BARD1 |
pancreatic ductal adenocarcinoma |
conservative_inframe_deletion |
2.852% (48/1683) |
1 entry |
ENSG00000138376 |
BARD1 |
embryonal rhabdomyosarcoma |
sequence_alteration |
2.326% (2/86) |
1 entry |
ENSG00000138376 |
BARD1 |
bladder transitional cell carcinoma |
missense_variant |
1.743% (8/459) |
1 entry |
ENSG00000138376 |
BARD1 |
large cell lung carcinoma |
sequence_alteration |
10.53% (2/19) |
2 entries |
ENSG00000138376 |
BARD1 |
basal cell carcinoma |
sequence_alteration |
10.29% (7/68) |
2 entries |
ENSG00000138376 |
BARD1 |
pancreatic ductal adenocarcinoma |
frameshift_variant |
2.852% (48/1683) |
1 entry |
ENSG00000138376 |
BARD1 |
lung adenocarcinoma |
stop_gained |
1.431% (39/2726) |
2 entries |
ENSG00000138376 |
BARD1 |
melanoma |
missense_variant |
3.448% (5/145) |
3 entries |
ENSG00000138376 |
BARD1 |
small cell lung carcinoma |
missense_variant |
0.6787% (3/442) |
2 entries |
ENSG00000138376 |
BARD1 |
cecum adenocarcinoma |
frameshift_variant |
3.042% (8/263) |
1 entry |
ENSG00000138376 |
BARD1 |
clear cell renal carcinoma |
missense_variant |
0.6008% (9/1498) |
1 entry |
ENSG00000138376 |
BARD1 |
bile duct adenocarcinoma |
missense_variant |
0.7712% (3/389) |
2 entries |
ENSG00000138376 |
BARD1 |
chronic lymphocytic leukemia |
sequence_alteration |
1.122% (10/891) |
1 entry |
ENSG00000138376 |
BARD1 |
Brain Stem Glioblastoma |
sequence_alteration |
3.571% (2/56) |
1 entry |
ENSG00000138376 |
BARD1 |
gastric adenocarcinoma |
missense_variant |
1.25% (9/720) |
2 entries |
ENSG00000138376 |
BARD1 |
breast carcinoma |
sequence_alteration |
0.5976% (9/1506) |
2 entries |
ENSG00000138376 |
BARD1 |
bile duct adenocarcinoma |
sequence_alteration |
0.7712% (3/389) |
2 entries |
ENSG00000138376 |
BARD1 |
non-small cell lung carcinoma |
sequence_alteration |
4.167% (4/96) |
3 entries |
ENSG00000138376 |
BARD1 |
colorectal adenocarcinoma |
frameshift_variant |
2.654% (31/1168) |
1 entry |
ENSG00000138376 |
BARD1 |
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
2.009% (13/647) |
1 entry |
ENSG00000138376 |
BARD1 |
brain glioblastoma |
sequence_alteration |
0.4125% (5/1212) |
3 entries |
ENSG00000138376 |
BARD1 |
pancreatic neuroendocrine tumor |
missense_variant |
4.661% (11/236) |
1 entry |
ENSG00000138376 |
BARD1 |
papillary thyroid carcinoma |
missense_variant |
0.2045% (1/489) |
1 entry |
ENSG00000138376 |
BARD1 |
Merkel cell skin cancer |
sequence_alteration |
1.075% (1/93) |
1 entry |
ENSG00000138376 |
BARD1 |
Invasive Breast Carcinoma |
sequence_alteration |
2.222% (1/45) |
1 entry |
ENSG00000138376 |
BARD1 |
Merkel cell skin cancer |
missense_variant |
1.075% (1/93) |
1 entry |
ENSG00000138376 |
BARD1 |
urothelial carcinoma |
frameshift_variant |
1.163% (1/86) |
1 entry |
ENSG00000138376 |
BARD1 |
breast carcinoma |
frameshift_variant |
0.5976% (9/1506) |
1 entry |
ENSG00000138376 |
BARD1 |
Anal Squamous Cell Carcinoma |
sequence_alteration |
1.22% (1/82) |
1 entry |
ENSG00000138376 |
BARD1 |
urothelial carcinoma |
stop_gained |
1.163% (1/86) |
1 entry |
ENSG00000138376 |
BARD1 |
head and neck squamous cell carcinoma |
sequence_alteration |
0.159% (1/629) |
1 entry |
ENSG00000138376 |
BARD1 |
colonic neoplasm |
sequence_alteration |
6.667% (1/15) |
1 entry |
ENSG00000138376 |
BARD1 |
colon carcinoma |
conservative_inframe_deletion |
25.0% (2/8) |
1 entry |
ENSG00000138376 |
BARD1 |
Intimal Sarcoma |
sequence_alteration |
12.5% (1/8) |
1 entry |
ENSG00000138376 |
BARD1 |
nasal cavity and paranasal sinus carcinoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000138376 |
BARD1 |
lung carcinoma |
conservative_inframe_deletion |
3.604% (4/111) |
1 entry |
ENSG00000138376 |
BARD1 |
colorectal adenocarcinoma |
stop_gained |
2.654% (31/1168) |
1 entry |
ENSG00000138376 |
BARD1 |
rectal adenocarcinoma |
frameshift_variant |
0.5495% (3/546) |
1 entry |
ENSG00000138376 |
BARD1 |
female breast carcinoma |
stop_gained |
1.873% (5/267) |
1 entry |
ENSG00000138376 |
BARD1 |
lung adenocarcinoma |
frameshift_variant |
1.431% (39/2726) |
1 entry |
ENSG00000138376 |
BARD1 |
oral squamous cell carcinoma |
missense_variant |
0.3788% (1/264) |
1 entry |
ENSG00000138376 |
BARD1 |
urothelial carcinoma |
sequence_alteration |
1.163% (1/86) |
1 entry |
ENSG00000138376 |
BARD1 |
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
1.111% (2/180) |
1 entry |
ENSG00000138376 |
BARD1 |
breast ductal adenocarcinoma |
stop_gained |
2.628% (42/1598) |
1 entry |
ENSG00000138376 |
BARD1 |
brain glioblastoma |
frameshift_variant |
0.4125% (5/1212) |
1 entry |
ENSG00000138376 |
BARD1 |
osteosarcoma |
sequence_alteration |
0.6579% (1/152) |
1 entry |
ENSG00000138376 |
BARD1 |
follicular thyroid carcinoma |
missense_variant |
1.449% (1/69) |
1 entry |
ENSG00000138376 |
BARD1 |
Invasive Breast Carcinoma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000138376 |
BARD1 |
mucosal melanoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000138376 |
BARD1 |
mucosal melanoma |
sequence_alteration |
1.429% (1/70) |
1 entry |
ENSG00000138376 |
BARD1 |
follicular thyroid carcinoma |
sequence_alteration |
1.449% (1/69) |
1 entry |
ENSG00000138376 |
BARD1 |
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000138376 |
BARD1 |
Adamantinomatous Craniopharyngioma |
sequence_alteration |
7.692% (1/13) |
1 entry |
ENSG00000138376 |
BARD1 |
Pancreatic Acinar Cell Carcinoma |
sequence_alteration |
2.941% (1/34) |
1 entry |
ENSG00000138376 |
BARD1 |
anaplastic oligodendroglioma |
sequence_alteration |
1.176% (1/85) |
1 entry |
ENSG00000138376 |
BARD1 |
Adrenal Gland Neuroblastoma |
missense_variant |
1.667% (1/60) |
1 entry |
ENSG00000138376 |
BARD1 |
pancreatic neuroendocrine tumor |
conservative_inframe_deletion |
4.661% (11/236) |
1 entry |
ENSG00000138376 |
BARD1 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
0.3788% (1/264) |
1 entry |
ENSG00000138376 |
BARD1 |
Adrenal Gland Neuroblastoma |
sequence_alteration |
1.667% (1/60) |
1 entry |
ENSG00000138376 |
BARD1 |
cecum adenocarcinoma |
stop_gained |
3.042% (8/263) |
1 entry |
ENSG00000138376 |
BARD1 |
oral squamous cell carcinoma |
sequence_alteration |
0.3788% (1/264) |
1 entry |
ENSG00000138376 |
BARD1 |
non-small cell lung carcinoma |
stop_gained |
4.167% (4/96) |
1 entry |
ENSG00000138376 |
BARD1 |
prostate carcinoma |
missense_variant |
1.878% (8/426) |
1 entry |
ENSG00000138376 |
BARD1 |
nasal cavity and paranasal sinus carcinoma |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000138376 |
BARD1 |
anaplastic oligodendroglioma |
missense_variant |
1.176% (1/85) |
1 entry |
ENSG00000138376 |
BARD1 |
bronchoalveolar adenocarcinoma |
sequence_alteration |
4.545% (1/22) |
1 entry |
ENSG00000138376 |
BARD1 |
diffuse large B-cell lymphoma |
missense_variant |
0.2703% (1/370) |
1 entry |
ENSG00000138376 |
BARD1 |
colon carcinoma |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000138376 |
BARD1 |
lung carcinoid tumor |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000138376 |
BARD1 |
lung carcinoid tumor |
sequence_alteration |
3.704% (1/27) |
1 entry |
ENSG00000138376 |
BARD1 |
colonic neoplasm |
missense_variant |
6.667% (1/15) |
1 entry |
ENSG00000138376 |
BARD1 |
diffuse large B-cell lymphoma |
sequence_alteration |
0.2703% (1/370) |
1 entry |
ENSG00000138376 |
BARD1 |
head and neck squamous cell carcinoma |
missense_variant |
0.159% (1/629) |
1 entry |
ENSG00000138376 |
BARD1 |
Intimal Sarcoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000138376 |
BARD1 |
rectal adenocarcinoma |
missense_variant |
0.5495% (3/546) |
1 entry |
ENSG00000138376 |
BARD1 |
Pancreatic Acinar Cell Carcinoma |
missense_variant |
2.941% (1/34) |
1 entry |
ENSG00000138376 |
BARD1 |
Adamantinomatous Craniopharyngioma |
missense_variant |
7.692% (1/13) |
1 entry |